Evidence map›Paper›PMID 37439234›Full record

ArticleAnatolian journal of cardiology2023

Risk Factors, Use of Preventive Drugs, and Cardiovascular Events in Diabetes Mellitus: The PURE Türkiye Cohort.

Aytekin Oğuz, Mustafa Kılıçkap, Sadi Guleç, Yüksel Altuntaş, Kubilay Karşıdağ, Ahmet Temizhan, Özge Telci Çaklılı, Kevser Burcu Tümerdem Çalık, Miraç Vural Keskinler, Sumathy Rangarajan and 1 more

Abstract read
In one paragraph

Article in Anatolian journal of cardiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Aytekin OğuzDepartment of Internal Medicine, Faculty of Medicine, İstanbul Medeniyet University, İstanbul, Türkiye.
Mustafa KılıçkapDepartment of Cardiology, Faculty of Medicine, Ankara University, Ankara, Türkiye.
Sadi GuleçDepartment of Cardiology, Faculty of Medicine, Ankara University, Ankara, Türkiye.
Yüksel AltuntaşDepartment of Endocrinology and Metabolism, Faculty of Medicine, University of Health Sciences, İstanbul Şişli Hamidiye Etfal Health Training and Research Hospital, İstanbul, Türkiye.
Kubilay KarşıdağDivision of Endocrinology, Department of Internal Medicine, Faculty of Medicine, İstanbul University, İstanbul, Türkiye.
Ahmet TemizhanClinic of Cardiology, University of Health Science, Ankara City Hospital, Ankara, Türkiye.
Özge Telci ÇaklılıDepartment of Endocrinology and Metabolism, Kocaeli City Hospital, Kocaeli, Türkiye.
Kevser Burcu Tümerdem ÇalıkDepartment of Health Administration, Marmara University Faculty of Health Sciences, İstanbul, Türkiye.
Miraç Vural KeskinlerDepartment of Internal Medicine, Faculty of Medicine, İstanbul Medeniyet University, İstanbul, Türkiye.
Sumathy RangarajanPopulation Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, ON, Canada.
Salim YusufPopulation Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, ON, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe risk of cardiovascular disease is correlated with the frequency and control of associated risk factors in diabetes mellitus and may vary according to country. We evaluated risk factors for cardiovascular disease, cardiovascular events, and the use of preventive medications in patients with diabetes mellitus using the Prospective Urban and Rural Epidemiological Türkiye cohort.

methodsPatients with diabetes mellitus versus without diabetes mellitus were compared for risk factors, cardioprotective drugs (angiotensin-converting enzyme inhibitors or angiotensin-II receptor antagonists, statins, and antiplatelets), and cardiovascular events. The primary outcome was major cardiovascular events (composite of cardiovascular death, myocardial infarction, stroke, or heart failure).

resultsAmong 4041 participants, 549 (13.6%) had diabetes mellitus. The mean age (54.8 ± 8.4 vs. 49.3 ± 9.0 years, P <.001) and proportion of women (65.4% vs. 59.9%, P =.014) were higher in diabetics compared with non-diabetics. Hypertension, history of coronary heart disease, and use of statin, antiplatelets, and angiotensin-converting enzyme inhibitors or angiotensin-II receptor antagonists were more common in diabetics; however, the use of these medications at baseline was lower than optimal even in patients with diabetes mellitus and concomitant coronary heart disease (statin 31.2%, antiplatelets 46.9%, and angiotensin-converting enzyme inhibitors or angiotensin-II receptor antagonists 54.7%). During 11.5 years of follow-up, major cardiovascular events occurred in 288 (7.1%) patients, and the risk was higher in diabetics [hazard ratio (95% confidence interval) 1.71 (1.30-2.24); P <.001]. The increase in the risk of future events was comparable for those with diabetes mellitus alone without cardiovascular disease [hazard ratio 1.62 (1.20-2.20)] versus those with cardiovascular disease alone without diabetes mellitus [hazard ratio 1.31 (0.83-2.07)] and was additive in those with both conditions [hazard ratio 2.79 (1.65-4.69)]. The risk of major coronary events (myocardial infarction, angina, percutaneous, or surgical coronary intervention) was also higher in diabetes mellitus [hazard ratio 1.64 (1.26-2.15); P <.001].

conclusionPatients with diabetes mellitus have a higher risk of major cardiovascular events, and the risk is comparable to that observed in those with cardiovascular disease but no diabetes mellitus. The use of preventive medicines for cardiovascular diseases is disturbingly low in diabetics.

Indexed as

Cardiovascular DiseasesCoronary DiseaseDiabetes MellitusHydroxymethylglutaryl-CoA Reductase InhibitorsMyocardial InfarctionAngiotensin-Converting Enzyme InhibitorsAngiotensin Receptor AntagonistsAngiotensinsFemaleHumansProspective StudiesRisk FactorsTreatment OutcomeAngiotensin-Converting Enzyme InhibitorsAngiotensin Receptor AntagonistsAngiotensinsHydroxymethylglutaryl-CoA Reductase Inhibitors

Identifiers

PMID37439234
PMCPMC10406140

What OpenQuestion holds

Texttitle and abstract
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.